Should I Buy BDMD? BDMD 2026 Analysis

Should You Buy Baird Medical Investment Holdings Ltd (BDMD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.070

1 Day change

52 Week Range

7.530

Analysis Updated At

2026/01/29

Baird Medical Investment Holdings Ltd (BDMD) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are bearish, the stock has shown consistent price declines, and there are no significant positive trading signals or catalysts to suggest immediate upside potential. While the company has made strategic partnerships recently, its financial performance remains weak, with negative net income and EPS. Given the lack of strong growth indicators and the absence of favorable trading trends, it is better to hold off on investing in this stock for now.

Technical Analysis

The technical indicators are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 34.555, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 1.013), with no clear upward momentum.

Options Data

Positive Catalysts

The company has recently entered a strategic partnership with Stonewood Key Capital to enhance global commercialization and operational efficiency. Additionally, it successfully hosted a medical masterclass in Shanghai, which could enhance its reputation in the medical field.

Neutral/Negative Catalysts

The stock has shown consistent price declines (-1.83% in the regular market and -0.93% post-market). Hedge funds and insiders are neutral, with no significant trading trends. The stock's forecast indicates a potential decline of -11.73% over the next month.

Financial Performance

In 2024/Q2, the company reported no revenue growth (0.00% YoY), a negative net income of -858,731, and an EPS of -0.43. While gross margin is high at 82.11%, the lack of revenue growth and negative profitability are concerning.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data is available for BDMD.

Analyst Rating

Wall Street analysts forecast BDMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDMD is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 1.070

Low

Averages

High